Premium
NAMA and AATOD warn Senators not to raise cap
Author(s) -
Knopf Alison
Publication year - 2020
Publication title -
alcoholism and drug abuse weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7591
pISSN - 1042-1394
DOI - 10.1002/adaw.32716
Subject(s) - alliance , political science , covid-19 , law , medicine , disease , pathology , infectious disease (medical specialty)
Last week, Mark W. Parrino, president of the American Association for the Treatment of Opioid Dependence (AATOD), and Zachary Talbott, president of the National Alliance for Medication Assisted Recovery (NAMA Recovery), wrote a letter to Congress warning against raising the DATA 2000 (buprenorphine prescribing) patient cap from 275 to 500 during the pandemic. The letter to Senators Ed Markey (D‐Mass.), Jeanne Shaheen (D‐N.H.), Maggie Hassan (D‐N.H.), Elizabeth Warren (D‐Mass.) and Dianne Feinstein (D‐Calif.) was in response to an April 17 letter from the senators to Health and Human Services Secretary Alex Azar and Assistant Secretary Elinore McCance‐Katz urging them to increase the cap.